Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 160
Filtrar
Mais filtros

País/Região como assunto
Intervalo de ano de publicação
1.
Cutan Ocul Toxicol ; 35(3): 222-7, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26339826

RESUMO

CONTEXT: Ethambutol-induced retinal oxidative damage in patients with tuberculosis is still not being adequately treated. The protective effect of thiamine pyrophosphate against oxidative damage in some tissues has been reported, but no information on the protective effects of thiamine pyrophosphate against ethambutol-induced oxidative retinal damage has been found in the medical literature. OBJECTIVE: The objective is to investigate whether thiamine pyrophosphate has a protective effect against oxidative retinal damage in rats induced by ethambutol. MATERIALS AND METHODS: Experimental animals divided into four groups (n = 10): the healthy group (HG), the ethambutol control group (EMB), thiamine + ethambutol group (Thi-EMB) and thiamine pyrophosphate + ethambutol group (TPP-EMB). The rats in the TPP-EMB and Thi-EMB groups were administered thiamine pyrophosphate and thiamine, respectively, at doses of 20 mg/kg intraperitoneally. Distilled water was administered intraperitoneally to the HG and the EMB groups as a solvent in the same volumes. One hour after drug injection, 30 mg/kg ethambutol was administered via an oral gavage to the TPP-EMB, Thi-EMB and EMB groups. This procedure was repeated once a day for 90 days. At the end of this period, all rats were euthanized under high-dose thiopental sodium anesthesia, and biochemical and histopathological investigations of the retinal tissue were performed. RESULTS: Malondialdehyde (MDA) and DNA damage product 8-hydroxyguanine levels were significantly lower in the retinal tissue of TPP-EMB and HG groups compared to those of the Thi-EMB and EMB groups, and total glutathione (tGSH) was also found to be higher. In addition, severe retinal tissue vascularization, edema and loss of ganglion cells were observed in the Thi-EMB and EMB groups, whereas histopathological findings for the TPP-EMB group were observed to be close to normal. DISCUSSION AND CONCLUSION: These findings suggest that thiamine pyrophosphate protects retinal tissues from ethambutol-induced oxidative damage, and thiamine does not. This positive effect of thiamine pyrophosphate may be useful in the prevention of ocular toxicity that occurs during ethambutol use.


Assuntos
Antioxidantes/uso terapêutico , Antituberculosos/efeitos adversos , Etambutol/efeitos adversos , Oftalmopatias/induzido quimicamente , Oftalmopatias/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico , Animais , Antioxidantes/farmacologia , Dano ao DNA , Olho/efeitos dos fármacos , Olho/metabolismo , Olho/patologia , Oftalmopatias/metabolismo , Oftalmopatias/patologia , Glutationa/metabolismo , Guanina/análogos & derivados , Guanina/metabolismo , Masculino , Malondialdeído/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Ratos Wistar , Tiamina/farmacologia , Tiamina/uso terapêutico , Tiamina Pirofosfato/farmacologia
2.
Lik Sprava ; (5-6): 126-32, 2015.
Artigo em Russo | MEDLINE | ID: mdl-27089730

RESUMO

In the article the results of clinical researches of efficiency of preparation of Cocarnit are resulted for patients after endoprosthesis of large joints. It is routine that for patients, receiving preparation of Cocarnit after the operation period there was a decline in the amount of complaints of patients on the total somatical state. Preparation of Ccocarnit was positively estimated outside patients, meaningful by-reactions, serving reason of abolition of preparation, was not marked. At the reception preparation of Cocarnit greater part of investigational laboratory indexes (table of contents of glucose, ß-lipoproteines, total chondroitisulfates, TBC-productes (malonic dyaldehyde), activity of aspartataminotransferase, alkaline phosphatase and ß-glutamyltranspeptidase), the indexes of clinical blood test and leucocytar indexes during a supervision did not have reliable differences from such as the persons of the control group, that confirms good bearab leness of the indicated preparation. Application preparation of Cocarnit for patients in composition the chart of treatment of patients after endoprosthesis of large joints brought maintenance over of cholesterol to the decline, glycoproteins, TBC-products (malonic dyaldehyde), activity of alaninaminotransferase, that specifies on normalizing influence of the indicated preparation in relation to the basic types of exchange of matters.


Assuntos
Artroplastia de Quadril/reabilitação , Artroplastia do Joelho/reabilitação , Articulação do Quadril/efeitos dos fármacos , Articulação do Joelho/efeitos dos fármacos , Substâncias Protetoras/uso terapêutico , Trifosfato de Adenosina/uso terapêutico , Adulto , Idoso , Fosfatase Alcalina/sangue , Aspartato Aminotransferases/sangue , Glicemia/metabolismo , Sulfatos de Condroitina/sangue , Combinação de Medicamentos , Feminino , Articulação do Quadril/metabolismo , Articulação do Quadril/patologia , Articulação do Quadril/cirurgia , Humanos , Articulação do Joelho/metabolismo , Articulação do Joelho/patologia , Articulação do Joelho/cirurgia , Lipoproteínas LDL/sangue , Masculino , Malondialdeído/sangue , Pessoa de Meia-Idade , Niacinamida/uso terapêutico , Estresse Oxidativo/efeitos dos fármacos , Satisfação do Paciente , Qualidade de Vida , Tiamina Pirofosfato/uso terapêutico , Vitamina B 12/uso terapêutico , gama-Glutamiltransferase/sangue
3.
Lik Sprava ; (7-8): 95-8, 2015.
Artigo em Ucraniano | MEDLINE | ID: mdl-27491158
4.
Lik Sprava ; (7-8): 141-8, 2015.
Artigo em Russo | MEDLINE | ID: mdl-27491167

RESUMO

In clinical trial included 41 patient with clinic-instrumental dates, which said about myocardium dysfunction and system diseases of connecting fabric and displays of CCI I-III of functional class (FC). Including of complex metabolic drug Cocarnit in standard therapy of systemdiseases of connecting fabric was instrumental in more expressed clinical improvement of patientsclinical dates in 15 days of supervision: a weakness diminished on 66.67%, shortbreathing at the insignificant physical loading--on 23.81%, at the ordinary physical loading--on 47.62%, at the megascopic physical loading--on 19.05%, pain in area of heart--on 42.85%, there are interruptions in-process heart--on 28.57%, oedematousness of shins--on 57.14%, sense of numbness, burning, sensitiveness to cold of extremities--on 57.14%. Quantity of patients with III FC diminished on 5 (23.81%), in a control group--on 2 (10%). It implementation of test with the 6-minute walking more expressed increase of the overcame distance is set for the patients of basicgroup--on 15.46% as compared to a control group--on 7.01%. Cocarnit patients estimatedpositively; side effects with subsequent abolition of drug, were not. Laboratory indexes (AlAT, AsAT, bilirubin, kreatinine, haemoglobin) at the end of trial did not change considerably, that confirmed good bearableness of drug.


Assuntos
Angina Pectoris/tratamento farmacológico , Cardiomiopatias/tratamento farmacológico , Cardiotônicos/uso terapêutico , Tecido Conjuntivo/efeitos dos fármacos , Dispneia/tratamento farmacológico , Insuficiência Cardíaca/prevenção & controle , Hipestesia/tratamento farmacológico , Trifosfato de Adenosina/uso terapêutico , Adulto , Idoso , Alanina Transaminase/sangue , Angina Pectoris/sangue , Angina Pectoris/patologia , Angina Pectoris/fisiopatologia , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Cardiomiopatias/sangue , Cardiomiopatias/patologia , Cardiomiopatias/fisiopatologia , Estudos de Casos e Controles , Tecido Conjuntivo/patologia , Creatinina/sangue , Combinação de Medicamentos , Dispneia/sangue , Dispneia/patologia , Dispneia/fisiopatologia , Feminino , Glicina/uso terapêutico , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/patologia , Insuficiência Cardíaca/fisiopatologia , Hemoglobinas/metabolismo , Humanos , Hipestesia/sangue , Hipestesia/patologia , Hipestesia/fisiopatologia , Masculino , Pessoa de Meia-Idade , Miocárdio/metabolismo , Miocárdio/patologia , Niacinamida/uso terapêutico , Tiamina Pirofosfato/uso terapêutico , Vitamina B 12/uso terapêutico
5.
J Pediatr ; 164(6): 1456-61, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24607240

RESUMO

OBJECTIVES: To compare blood thiamine concentrations, echocardiography findings, and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in infants with clinically diagnosed beriberi and healthy matched controls, and to evaluate changes after thiamine treatment. STUDY DESIGN: Sixty-two Cambodian infants (20 cases and 42 controls), aged 2-47 weeks, were enrolled in this prospective study. Echocardiography and phlebotomy were performed at baseline and after thiamine treatment. RESULTS: Both cases and controls were thiamine-deficient, with median blood thiamine diphosphate (TDP) concentrations of 47.6 and 55.1 nmol/L, respectively (P = .23). All subjects had normal left ventricular ejection fraction. The median NT-proBNP concentration in cases (340 pg/mL [40.1 pmol/L]) was higher than previously reported normal ranges, but not statistically significantly different from that in controls (175 pg/mL [20.7 pmol/L]) (P = .10), and was not correlated with TDP concentration (P = .13). Two cases with the lowest baseline TDP concentrations (24 and 21 nmol/L) had right ventricular enlargement and elevated NT-proBNP levels that improved dramatically by 48 hours after thiamine administration. CONCLUSION: Only a minority of thiamine-deficient Cambodian infants demonstrate abnormal echocardiography findings. Thiamine deficiency produces echocardiographic evidence of right ventricular dysfunction, but this evidence is not apparent until deficiency is severe. NT-proBNP concentrations are mildly elevated in sick infants with normal echocardiography findings, indicating possible physiological changes not yet associated with echocardiographic abnormalities.


Assuntos
Peptídeo Natriurético Encefálico/sangue , Fragmentos de Peptídeos/sangue , Deficiência de Tiamina/complicações , Tiamina Pirofosfato/uso terapêutico , Disfunção Ventricular Esquerda/etiologia , Povo Asiático/estatística & dados numéricos , Beriberi/sangue , Beriberi/complicações , Beriberi/etnologia , Biomarcadores/metabolismo , Estudos de Casos e Controles , Ecocardiografia Doppler/métodos , Feminino , Seguimentos , Testes de Função Cardíaca , Humanos , Lactente , Recém-Nascido , Masculino , Valores de Referência , Medição de Risco , Índice de Gravidade de Doença , Deficiência de Tiamina/sangue , Deficiência de Tiamina/tratamento farmacológico , Deficiência de Tiamina/etnologia , Tiamina Pirofosfato/sangue , Resultado do Tratamento , Disfunção Ventricular Esquerda/diagnóstico , Disfunção Ventricular Esquerda/etnologia
6.
ScientificWorldJournal ; 2013: 182694, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24163613

RESUMO

OBJECTIVE: The aim of this study was to evaluate the effectiveness of thiamine pyrophosphate against cisplatin-induced ototoxicity in guinea pigs. MATERIALS AND METHODS: Healthy guinea pigs (n = 18) were randomly divided into three groups. Group 1 (n = 6) received an intraperitoneal injection of saline solution and cisplatin for 7 days, group 2 (n = 6) received an intraperitoneal injection of thiamine pyrophosphate and cisplatin for 7 days, and group 3 (n = 6) received only intraperitoneal injection of saline for 7 days. The animals in all groups were sacrificed under anesthesia, and their cochleas were harvested for morphological and biochemical observations. RESULTS: In group 1, receiving only cisplatin, cochlear glutathione concentrations, superoxide dismutase, and glutathione peroxidase activities significantly decreased (P < 0.05) and malondialdehyde concentrations significantly increased (P < 0.05) compared to the control group. In group 2, receiving thiamine pyrophosphate and cisplatin, the concentrations of enzymes were near those of the control group. Microscopic examination showed that outer hair cells, spiral ganglion cells, and stria vascularis were preserved in group 2. CONCLUSION: Systemic administration of thiamine pyrophosphate yielded statistically significant protection to the cochlea of guinea pigs from cisplatin toxicity. Further experimental animal studies are essential to determine the appropriate indications of thiamine pyrophosphate before clinical use.


Assuntos
Cisplatino/toxicidade , Tiamina Pirofosfato/uso terapêutico , Animais , Antioxidantes/metabolismo , Cóclea/efeitos dos fármacos , Cóclea/metabolismo , Glutationa/metabolismo , Cobaias , Masculino , Modelos Animais
7.
Eur J Clin Nutr ; 77(7): 757-760, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-36859659

RESUMO

Thiamine deficiency, commonly presenting as dry and wet beriberi, a lesser-known entity in the present era, is increasingly being reported from Kashmir, a north Indian state. The present study aims to present the clinical profile of patients presenting with high-output heart failure (HOHF). Subjects with a primary diagnosis of denovo heart failure and features suggestive of HOHF were recruited; those who responded to intravenous administration of thiamine alone (responders) were adults with no co-morbidities and those who required other medications particularly diuretics (non-responders) were elderly with co-morbidities and underlying heart disease. Responders showed considerably lower mean thiamine pyrophosphate (TPP) levels and higher mean lactate and venous oxygen saturation than non-responders. More importantly, the mean drop in lactate and SVO2 following thiamine therapy was more in responders. In a setting of high risk for thiamine deficiency, features suggestive of HOHF along with elevated lactate and higher venous oxygen saturation, a response to thiamine challenge may serve as surrogate marker of thiamine deficiency.


Assuntos
Beriberi , Insuficiência Cardíaca , Deficiência de Tiamina , Humanos , Adulto , Idoso , Tiamina/uso terapêutico , Deficiência de Tiamina/tratamento farmacológico , Beriberi/tratamento farmacológico , Beriberi/diagnóstico , Insuficiência Cardíaca/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico
8.
Lik Sprava ; (3-4): 75-81, 2012.
Artigo em Ucraniano | MEDLINE | ID: mdl-23356142

RESUMO

Left ventricular diastolic dysfunction in patients with diabetes is formed in the absence of atherosclerotic changes as a consequence of diabetic cardiac autonomic neuropathy in the early stages of diabetes. Progression of autonomic cardiac neuropathy in cardio-vascular type is associated with the violation of energy supply of cells, protein synthesis, electrolyte exchange, the exchange of trace elements, oxidation reduction processes, oxygen-transport function of blood, so that metabolic therapy is carried out to optimize the processes of formation and energy costs. The drug cocarnit activates processes of aerobic oxidation of glucose, as well as providing regulatory influence on the oxidation of fatty acids. Applying of cocarnit in complex therapy in patients with diabetic cardiac autonomic neuropathy found improvement of left ventricular diastolic function, and positive dynamics in the efferent activity balance of the sympathetic and parasympathetic control of heart rate variability, which provides the regression of clinical symptoms.


Assuntos
Cardiomiopatias/tratamento farmacológico , Cardiotônicos/uso terapêutico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Neuropatias Diabéticas/tratamento farmacológico , Disfunção Ventricular Esquerda/tratamento farmacológico , Trifosfato de Adenosina/farmacologia , Trifosfato de Adenosina/uso terapêutico , Adolescente , Adulto , Sistema Nervoso Autônomo/efeitos dos fármacos , Sistema Nervoso Autônomo/metabolismo , Cardiomiopatias/complicações , Cardiomiopatias/metabolismo , Cardiotônicos/farmacologia , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/metabolismo , Neuropatias Diabéticas/complicações , Neuropatias Diabéticas/metabolismo , Combinação de Medicamentos , Ácidos Graxos/metabolismo , Feminino , Glucose/metabolismo , Coração/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Niacinamida/farmacologia , Niacinamida/uso terapêutico , Oxirredução , Tiamina Pirofosfato/farmacologia , Tiamina Pirofosfato/uso terapêutico , Disfunção Ventricular Esquerda/complicações , Disfunção Ventricular Esquerda/metabolismo , Função Ventricular Esquerda/efeitos dos fármacos , Função Ventricular Esquerda/fisiologia , Vitamina B 12/farmacologia , Vitamina B 12/uso terapêutico
9.
Neuropathology ; 30(1): 36-43, 2010 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-19563509

RESUMO

Disability after traumatic spinal cord injury (TSCI) results from physical trauma and from "secondary mechanisms of injury" such as low metabolic energy levels, oxidative damage and lipid peroxidation. In order to prove if early metabolic reactivation is a better therapeutic option than antioxidant therapy in the acute phase of TSCI, spinal cord contusions were performed in adult rats using a well-characterized weight drop technique at thoracic 9 level. After TSCI, pyrophosphate of thiamine or non-degradable cocarboxylase (NDC) enzyme was used to maintain energy levels, antioxidants such as superoxide dismutase and catalase (ANT) were used to decrease oxidative damage and methylprednisolone (MP), which has both therapeutic properties, was used as a control. Rats were divided into one sham group and six with TSCI; one of them received no treatment, and the rest were treated with NDC, MP, NDC + MP, NDC + ANT or ANT. The ANT group decreased lactate and creatine phosphokinase levels and increased the amount of preserved tissue (morphometric analysis) as well as functional recovery (Basso, Beattie and Bresnahan or BBB motor scale). In contrast, NDC treatment increased lipid peroxidation, measured through thiobarbituric acid reactive substances (TBARS) levels, as well as spinal cord tissue destruction and functional deficit. Early metabolic reactivation after a TSCI may be deleterious, while natural early metabolic inhibition may not be a "secondary mechanism of injury" but a "secondary neuroprotective response". While increased antioxidant defence after a TSCI may currently be an ideal therapeutic strategy, the usefulness of metabolic reactivation should be tested in the sub-acute or chronic phases of TSCI and new strategies must continue to be tested for the early ones.


Assuntos
Antioxidantes/uso terapêutico , Traumatismos da Medula Espinal/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico , Complexo Vitamínico B/uso terapêutico , Doença Aguda , Envelhecimento , Animais , Catalase/uso terapêutico , Creatina Quinase/metabolismo , Feminino , Ácido Láctico/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Distribuição Aleatória , Ratos , Ratos Long-Evans , Recuperação de Função Fisiológica , Medula Espinal/efeitos dos fármacos , Medula Espinal/metabolismo , Medula Espinal/patologia , Traumatismos da Medula Espinal/metabolismo , Traumatismos da Medula Espinal/patologia , Superóxido Dismutase/uso terapêutico , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Resultado do Tratamento
10.
BMC Pharmacol Toxicol ; 20(1): 40, 2019 07 05.
Artigo em Inglês | MEDLINE | ID: mdl-31277705

RESUMO

BACKGROUND: We aimed to determine the protective effects of thiamine pyrophosphate on ethanol induced optic neuropathy in an experimental model. METHODS: The rats were assigned into 4 groups, with 6 rats in each group as follows: healthy controls (HC group), only ethanol administered group (EtOH group), ethanol + thiamine pyrophosphate (20 mg/kg) administered group (TEt-20 group), and only thiamine pyrophosphate (20 mg/kg) (TPG group) administered group. To the rats in TEt-20 and TPG groups, 20 mg/kg thiamine pyrophosphate was administered via intraperitoneal route. To the rats in HC and EtOH groups, the same volume (0.5 ml) of distilled water as solvent was applied in the same manner. To the rats in TEt-20 and EtOH groups, one hour after application of thiamine pyrophosphate or distilled water, 32% ethanol with a dose of 5 g/kg was administered via oral gavage. This procedure was repeated once a day for 6 weeks. From the blood samples and tissues obtained from the rats, Malondialdehyde (MDA), reduced glutathione (GSH), interleukin 1 beta (IL-1ß) and tumor necrosis factor alpha (TNF-α) levels were studied. Histopathological evaluations were performed to the optic nerve tissue. RESULTS: Serum and tissue IL-1ß, TNF-α and MDA levels were the highest in EtOH group which were significantly lower in thiamine pyrophosphate administered group (TEt-20 group) (p: 0.001). Serum and tissue reduced GSH levels were the lowest in EtOH group which were also significantly higher in TEt-20 group (p:0.001). In histopathological evaluations, in EtOH group there was obvious destruction and edema with hemorrhage and dilated blood vessels which were not present in any other groups. CONCLUSIONS: There was an apparent destruction in ethanol administered group in histopathological analyses with an augmented level of oxidative stress markers and all those alterations were prevented with concomitant thiamine pyrophosphate administration. These protective effects of thiamine pyrophosphate are extremely important in chronic ethanol consumption. Clinical studies are warranted to define the exact role of thiamine pyrophosphate in prevention of ethanol induced optic neuropathy.


Assuntos
Etanol/toxicidade , Traumatismos do Nervo Óptico/induzido quimicamente , Traumatismos do Nervo Óptico/tratamento farmacológico , Substâncias Protetoras/uso terapêutico , Tiamina Pirofosfato/uso terapêutico , Animais , Glutationa/metabolismo , Interleucina-1beta/metabolismo , Masculino , Malondialdeído/metabolismo , Nervo Óptico/efeitos dos fármacos , Nervo Óptico/metabolismo , Nervo Óptico/patologia , Traumatismos do Nervo Óptico/metabolismo , Substâncias Protetoras/farmacologia , Ratos Wistar , Tiamina Pirofosfato/farmacologia , Fator de Necrose Tumoral alfa/metabolismo
11.
Artigo em Russo | MEDLINE | ID: mdl-29460903

RESUMO

AIM: To study the efficacy of the complex therapy, including cocarnit (group B vitamins, triphosadenine and nicotinamide), of diabetic neuropathy. MATERIAL AND METHODS: Forty-one patients with diabetes mellitus type 2 and distal symmetric sensorimotor polyneuropathy were examined. Patients were divided into 2 groups. Patients of the main group (n=26) received complex therapy, including cocarnit, and patients of the comparison group (n=15) received standard treatment. RESULTS AND CONCLUSION: The positive dynamics based on the VAS (р=0.0001), TSS (р=0.0001), NSS (р=0.001), NDS (р=0.0431), SF-36 (р=0.0008), electroneuromyographic results and glycated hemoglobin levels was observed in the main group. In patients of the comparison group, the positive dynamics was instable; the scores of clinical scales did not reach statistical significance. The results suggest the use of cocarnit in the complex treatment of patients with diabetic neuropathy.


Assuntos
Trifosfato de Adenosina/uso terapêutico , Diabetes Mellitus Tipo 2/complicações , Neuropatias Diabéticas/tratamento farmacológico , Neuropatias Diabéticas/etiologia , Niacinamida/uso terapêutico , Tiamina Pirofosfato/uso terapêutico , Vitamina B 12/uso terapêutico , Complexo Vitamínico B/uso terapêutico , Neuropatias Diabéticas/fisiopatologia , Combinação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Escala Visual Analógica
12.
Acta Cir Bras ; 31(3): 168-75, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27050787

RESUMO

PURPOSE: To investigate the effects of thiamine pyrophosphate (TPP) against desflurane induced hepatotoxicity. METHODS: Thirty experimental animals were divided into groups as healthy (HG), desflurane control (DCG) , TPP and desflurane group (TDG). 20 mg/kg TPP was injected to intraperitoneally TDG. After one hour of TPP administration, desflurane was applied for two hours. After 24 hours, liver tissues of the animals killed with decapitation were removed. The oxidant/antioxidant levels and ALT, AST and LDH activities were measured. The histopathological examinations were performed in the liver tissues for all rats. RESULTS: Notwithstanding the levels of oxidants and liver enzymes were significantly increased (p<0.0001), antioxidant levels were significantly decreased in DCG (p<0.0001). On contrary to the antioxidant parameters were increased (p<0.05) the oxidant parameters and liver enzymes were decreased in TDG (p<0.0001). Whereas multiple prominent, congestion, hemorrhage and dilatation were observed in sinusoids and lymphocyte-rich inflammation results in the centrilobular and portal areas of liver tissue in DCG, these findings were observed less frequently in TDG. CONCLUSION : Thiamine pyrophosphate prevented liver oxidative damage induced with desflurane and may be useful in prophylaxis of desflurane induced hepatotoxicity.


Assuntos
Anestésicos Inalatórios/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Isoflurano/análogos & derivados , Substâncias Protetoras/farmacologia , Tiamina Pirofosfato/uso terapêutico , Alanina Transaminase/efeitos dos fármacos , Alanina Transaminase/metabolismo , Animais , Aspartato Aminotransferases/efeitos dos fármacos , Aspartato Aminotransferases/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Desflurano , Glutationa/efeitos dos fármacos , Glutationa/metabolismo , Isoflurano/efeitos adversos , L-Lactato Desidrogenase/efeitos dos fármacos , L-Lactato Desidrogenase/metabolismo , Fígado/enzimologia , Fígado/patologia , Masculino , Malondialdeído/metabolismo , Modelos Animais , Óxido Nítrico/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Peroxidase/efeitos dos fármacos , Peroxidase/metabolismo , Ratos Wistar
13.
Basic Clin Pharmacol Toxicol ; 118(1): 70-6, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26432613

RESUMO

The aim of this study was to investigate whether thiamine pyrophosphate (TPP) has biochemical and histological preventive effects on oxidative liver damage induced by paracetamol (APAP). Rats were divided into the following groups: healthy control (HG), APAP (AG, 1500 mg/kg, orally), thiamine pyrophosphate (TPPG, 100 mg/kg, intraperitoneally), APAP+NAC (ANAC, 100 mg/kg, intraperitoneally), APAP+TPP (ATPG) and APAP+NAC+TPP (ANTG). Oxidant, antioxidant parameters, liver function tests and histological assessment were performed between groups. Malondialdehyde levels in the AG, HG, TPPG, ANAC, ATPG and ANTG groups were 0.470 ± 0.210, 0.213 ± 0.004, 0.194 ± 0.001, 0.197 ± 0.06, 0.199 ± 0.008 and 0.173 ± 0.010 µmol/g protein, respectively. Total glutathione levels were 7.787 ± 0.395, 14.925 ± 0.932, 13.200 ± 0.984, 13.162 ± 0.486, 13.287 ± 0.787 and 13.500 ± 0.891 µm/g protein, respectively. In the AG group, marked liver damage occurred with the elevation of liver function tests and oxidative stress markers, such as malondialdehyde, myeloperoxidase and nitric oxide (p < 0.05). Biochemical results were congruent with the histological changes of oxidative damage. Compared to the AG group (p < 0.05), TPP significantly reduced oxidant parameter levels in the ATPG group and simultaneously increased the antioxidant parameter levels of catalase and glutathione. The histological changes were improved to almost normal hepatic structure. Moreover, TPP had nearly the same hepatoprotective effect as NAC, and there was statistically no additional benefit with NAC co-treatment. There was no statistically significant difference (p > 0.05) among the ANAC, ANTG and ATPG groups in terms of oxidant/antioxidant levels. TPP proved to be as efficacious as standard therapy and may be beneficial in APAP-induced hepatotoxicity.


Assuntos
Acetaminofen/toxicidade , Antioxidantes/uso terapêutico , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Fígado/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Tiamina Pirofosfato/uso terapêutico , Acetilcisteína/administração & dosagem , Acetilcisteína/uso terapêutico , Animais , Antioxidantes/administração & dosagem , Catalase/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/patologia , Quimioterapia Combinada , Feminino , Glutationa/metabolismo , Fígado/metabolismo , Fígado/patologia , Testes de Função Hepática , Malondialdeído/metabolismo , Óxido Nítrico/metabolismo , Peroxidase/metabolismo , Ratos Wistar , Tiamina Pirofosfato/administração & dosagem
14.
Am Surg ; 53(12): 721-5, 1987 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-3425997

RESUMO

Cocarboxylase, or thiamine pyrophosphate, is an essential coenzyme in the catabolism of pyruvate. The authors evaluated the effects of a stable cocarboxylase solution in the treatment of an experimentally created acute myocardial infarction in 14 healthy mongrel dogs. The left anterior descending artery was ligated for 60 minutes and data were collected at the following points: A) prior to ligation, B) 15 minutes after ligation, C) 30 minutes after ligation, and D) 60 minutes after ligation. In one group (Group II), cocarboxylase (150 mgm/kg) was given systematically via a central line 15 minutes and 45 minutes after ligation, while in Group I an equal amount of D5W was given. Hemodynamic data include heart rate, systolic and mean arterial pressure, pulmonary wedge pressure, right arterial pressure, and cardiac output. Myocardial O2 consumption was determined by the method of Rooke and Feigl. Electrocardiographic data were also monitored throughout the experiment. In both groups, preligation (point A) hemodynamic data were similar. In Group II, there were beneficial hemodynamic changes versus Group I (expressed as percentage recovery of hemodynamic performance from preligation) at points C and D, with significant (P less than 0.05) decreases in heart rate, increased stroke volume, decreased systemic vascular resistance, and decreased myocardial O2 consumption. EKG criteria also showed improvement in Group II versus Group I. In conclusion, this experiment suggests that cocarboxylase may be beneficial to ischemic canine myocardium by virtue of its favorable systemic hemodynamic effects.


Assuntos
Hemodinâmica/efeitos dos fármacos , Infarto do Miocárdio/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico , Animais , Cães , Eletrocardiografia , Microscopia Eletrônica , Mitocôndrias Cardíacas/ultraestrutura , Infarto do Miocárdio/patologia
15.
J Int Med Res ; 5(1): 68-70, 1977.
Artigo em Inglês | MEDLINE | ID: mdl-320062

RESUMO

A preparation claimed to help patients to break the habit of smoking has recently been introduced. Material released in the mouth from a chewing gum causes an unpleasant taste when tobacco smoke is inhaled. This claim has been investigated in a double-blind trial on sixty subjects, thirty of whom took the active chewing gum and thirty the placebo chewing gum. The subjects each used one piece of chewing gum four times a day over a period of two weeks. This investigation clearly indicates that the active chewing gum is effective as an anti-smoking preparation, when used over a period of two weeks and the effect is still demonstrable one month later, although to a lesser extent.


Assuntos
Goma de Mascar , Prevenção do Hábito de Fumar , Acetatos/uso terapêutico , Adulto , Cloreto de Amônio/uso terapêutico , Ensaios Clínicos como Assunto , Combinação de Medicamentos , Humanos , Placebos , Prata/uso terapêutico , Tiamina Pirofosfato/uso terapêutico
16.
Kardiologiia ; 16(11): 133-6, 1976 Nov.
Artigo em Russo | MEDLINE | ID: mdl-1011453

RESUMO

In patients with active rheumatism the activity of the key enzymes of the pentose cycle -- glucoso-6-phosphatedehydrogenase and transketolase -- increases in the erythrocytes of the peripheral blood parallel with the severity of the inflammatory lesion of the heart. In patients with distrophic changes in the myocardium without concomitant carditis the level of glucoso-6-phosphatedehydrogenase did not change significantly, while the content of transketolase decreased considerably. Antirheumatic therapy helping to reduce the inflammatory reactions in the heart results in a reduction of the level of pentose cycle enzymes. The study of the ratio between glucoso-6-phosphatedehydrogenase and transketolase may prove valuable for an approximate evaluation of the predominance of inflammatory or dystrophic processes in the cardiac muscle.


Assuntos
Eritrócitos/enzimologia , Glucosefosfato Desidrogenase/sangue , Cardiopatia Reumática/sangue , Transcetolase/sangue , Adolescente , Adulto , Ensaios Enzimáticos Clínicos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Cardiopatia Reumática/tratamento farmacológico , Tiamina/uso terapêutico , Tiamina Pirofosfato/uso terapêutico
17.
Kardiologiia ; 15(2): 17-22, 1975 Feb.
Artigo em Russo | MEDLINE | ID: mdl-1123871

RESUMO

Chronic hypoxia arising in cases of circulatory insufficiency brings on changes in all kinds of metabolism, including that of energy and protein. Patients suffering from circulatory insufficiency should be treated with due regard for metabolic shifts occurring in cases of cardiac incompetence. A total of 180 patients with circulatory insufficiency of the I-IIIstage were examined by employing up-to-date methods in studying the state of the energy, carbohydrate, protein, amino acids metabolism and the hepatic function. The patients underwent medication with drugs influencing the metabolic processes and with combinations of such drugs and the clinical effect of such a type of the treatment is assessed.


Assuntos
Insuficiência Cardíaca/metabolismo , Proteínas/metabolismo , Trifosfato de Adenosina/uso terapêutico , Doença Crônica , Metabolismo Energético , Insuficiência Cardíaca/complicações , Humanos , Hipóxia/tratamento farmacológico , Hipóxia/etiologia , Hipóxia/metabolismo , Inosina/uso terapêutico , Oxirredução , Doença Cardiopulmonar/complicações , Doença Cardiopulmonar/metabolismo , Cardiopatia Reumática/complicações , Cardiopatia Reumática/metabolismo , Tiamina Pirofosfato/uso terapêutico
18.
Vopr Med Khim ; 34(3): 45-8, 1988.
Artigo em Russo | MEDLINE | ID: mdl-3420810

RESUMO

Metabolism of aminopyrine, sodium benzoate and toxicity of cyclophosphamide were studied in 185 male rats under conditions of various content of vitamin B1 in the animals. Deficiency of thiamin led to an increase in excretion of 4-aminoantipyrine and especially of its acetylated derivative. After administration of thiamin metabolism of aminopyrine was not distinctly altered, while thiamin diphosphate inhibited the drug biotransformation. In deficiency of vitamin B1 transformation of benzoic acid into hippuric acid was inhibited but formation of glucuronides was elevated. Administration of thiamin or thiamin diphosphate stimulated the benzoic acid conjugation and inhibited the glucuronides formation. Deficiency of vitamin B1 accelerated the cyclophosphamide toxicity. Preadministration of thiamin and especially of thiamin diphosphate decreased the toxic effect of cyclophosphamide.


Assuntos
Aminopirina/farmacocinética , Benzoatos/farmacocinética , Ciclofosfamida/toxicidade , Deficiência de Tiamina/metabolismo , Tiamina/uso terapêutico , Animais , Ácido Benzoico , Biotransformação , Ciclofosfamida/farmacocinética , Masculino , Ratos , Ratos Endogâmicos , Deficiência de Tiamina/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico
19.
Lik Sprava ; (5): 79-82, 1999 Jul.
Artigo em Ucraniano | MEDLINE | ID: mdl-10822685

RESUMO

A pharmacologic investigation confirmed the possibility of deliberate correction of pharmacological properties of the nonsteroidal anti-inflammatory preparation orthophen in a clinical setting by combining it with those drugs (cimetidin and cocarboxylase) capable of inhibiting elimination of orthophen from the body. In consequence, the level of the drug gets elevated not only in blood plasma but also in the synovial fluid of those joints affected by inflammation, which fact secures high efficiency of the antiinflammatory therapy.


Assuntos
Anti-Inflamatórios não Esteroides/análise , Artrite Reumatoide/metabolismo , Diclofenaco/análise , Líquido Sinovial/química , Analgésicos não Narcóticos/uso terapêutico , Anti-Inflamatórios não Esteroides/farmacocinética , Anti-Inflamatórios não Esteroides/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Cimetidina/uso terapêutico , Diclofenaco/farmacocinética , Diclofenaco/uso terapêutico , Quimioterapia Combinada , Humanos , Tiamina Pirofosfato/uso terapêutico , Fatores de Tempo , Distribuição Tecidual
20.
Klin Lab Diagn ; (3): 15-7, 1993.
Artigo em Russo | MEDLINE | ID: mdl-8963529

RESUMO

The authors describe a method for the prediction of the therapeutic effect of energy-stabilizing drugs, that helps rapidly select the optimal individual therapeutic policy. The method is based on measurement of the red cell ATP concentration in the course of in vitro incubation of cells in polyionic medium with the drug, and may be used in various diseases associated with energy metabolism disorders on the cellular level. The authors have used this method for the selection of a thiamine drug to be included in therapy of a diabetic in the period of the disease compensation.


Assuntos
Adenina/uso terapêutico , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/metabolismo , Metabolismo Energético/efeitos dos fármacos , Insulina/uso terapêutico , Tiamina Pirofosfato/uso terapêutico , Tiamina/uso terapêutico , Adenina/administração & dosagem , Trifosfato de Adenosina/sangue , Células Cultivadas , Diabetes Mellitus/sangue , Quimioterapia Combinada , Eritrócitos/metabolismo , Humanos , Insulina/administração & dosagem , Masculino , Modelos Biológicos , Tiamina/administração & dosagem , Tiamina Pirofosfato/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA